Alkermes Plc
ALKS
查看詳細走勢圖
28.520USD
+0.030+0.11%
收盤 12/24, 16:00（美東）報價延遲15分鐘
4.71B總市值
13.82本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+0.11%
5天
+2.55%
1月
-1.62%
6月
-1.31%
今年開始到現在
-0.83%
1年
-3.81%
查看詳細走勢圖
TradingKey Alkermes Plc股票評分
單位: USD 更新時間: 2025-12-24操作建議
Alkermes Plc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名16/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價43.88。中期看，股價處於平穩狀態。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Alkermes Plc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
17
分析師
買入
評級
43.875
目標均價
+49.18%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Alkermes Plc亮點
亮點風險
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
業績高增長
公司營業收入穩步增長，連續3年增長40.10%
估值合理
公司最新PE估值13.82，處於3年歷史合理位
機構減倉
最新機構持股175.23M股，環比減少0.01%
查克·羅伊斯持倉
明星投資者查克·羅伊斯持倉，最新持倉49.77K股
活躍度降低
近期活躍度降低，過去20天平均換手率-0.31
Alkermes Plc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Alkermes Plc簡介
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
公司代碼ALKS
公司Alkermes Plc
CEOPops (Richard F)
網址https://www.alkermes.com/
常見問題
Alkermes Plc(ALKS)的當前股價是多少？
Alkermes Plc(ALKS)的當前股價是 28.520。
Alkermes Plc 的股票代碼是什麼？
Alkermes Plc的股票代碼是ALKS。
Alkermes Plc股票的52週最高點是多少？
Alkermes Plc股票的52週最高點是36.450。
Alkermes Plc股票的52週最低點是多少？
Alkermes Plc股票的52週最低點是25.165。
Alkermes Plc的市值是多少？
Alkermes Plc的市值是4.71B。
Alkermes Plc的淨利潤是多少？
Alkermes Plc的淨利潤為367.07M。
現在Alkermes Plc(ALKS)的股票是買入、持有還是賣出？
根據分析師評級，Alkermes Plc(ALKS)的總體評級為買入，目標價格為43.875。
Alkermes Plc(ALKS)股票的每股收益（EPS TTM）是多少
Alkermes Plc(ALKS)股票的每股收益（EPS TTM）是2.064。
相關品種
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
